Arrowhead Pharmaceuticals Inc
$ 84.65
-3.06%
31 Jul - close price
- Market Cap 12,299,636,000 USD
- Current Price $ 84.65
- High / Low $ 87.10 / 84.53
- Stock P/E N/A
- Book Value 4.37
- EPS -2.27
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.07 %
- ROE -0.42 %
- 52 Week High 95.49
- 52 Week Low 15.01
About
Arrowhead Pharmaceuticals, Inc. develops drugs for the treatment of intractable diseases in the United States. The company is headquartered in Pasadena, California.
Analyst Target Price
$106.09
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-05 | 2025-11-25 | 2025-08-07 | 2025-05-12 | 2025-02-10 | 2024-11-26 | 2024-08-08 | 2024-05-09 | 2024-02-06 | 2023-11-29 | 2023-08-07 |
| Reported EPS | -0.93 | 0.22 | -0.11 | -1.26 | 2.75 | -1.39 | -1.37 | -1.38 | -1.02 | -1.24 | -1.02 | -0.96 |
| Estimated EPS | -1.11 | -0.37 | -0.3099 | -0.94 | -0.46 | -0.72 | -0.922 | -0.59 | -0.2 | -0.83 | -0.6 | -0.53 |
| Surprise | 0.18 | 0.59 | 0.1999 | -0.32 | 3.21 | -0.67 | -0.448 | -0.79 | -0.82 | -0.41 | -0.42 | -0.43 |
| Surprise Percentage | 16.2162% | 159.4595% | 64.5047% | -34.0426% | 697.8261% | -93.0556% | -48.59% | -133.8983% | -410% | -49.3976% | -70% | -81.1321% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -1.19 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ARWR
2026-07-31 15:39:42
Vanguard Portfolio Management LLC, along with its affiliates, has reported a beneficial ownership of 6,384,903 shares in Arrowhead Pharmaceuticals Inc. (ARWR), representing a 4.53% stake in the company. This disclosure, filed as a SCHEDULE 13G/A, indicates that Vanguard Portfolio Management has sole voting power over 33,548 shares and sole dispositive power over all 6.38 million shares. The filing clarifies that no single individual investor within Vanguard's managed accounts holds more than 5% of Arrowhead's common stock.
2026-07-31 07:11:38
B. Riley Securities has reiterated its Buy rating for Arrowhead Pharmaceuticals (ARWR.US) and increased the price target to $123. This adjustment reflects the firm's continued confidence in the company's financial prospects and market position.
2026-07-30 17:10:43
Arrowhead Pharmaceuticals (ARWR) appears to be 3% undervalued, according to a recent analysis, following positive late-stage trial data for two RNA interference programs. The company's stock has seen significant momentum, with a 7x return over the past year, driven by reassessments of its risk and opportunity mix. While a discounted cash flow model suggests the stock is heavily undervalued, the narrative relies on revenue growth, margin expansion, and successful trial progression, making it sensitive to potential setbacks.
2026-07-28 20:10:18
Arrowhead Pharmaceuticals, Inc.'s stock 12-month price target has been increased from $104.7 to $105.4 by analysts, indicating a potential 23% upside from its July 27th closing price. The consensus rating from 14 analysts remains a "Buy," with a range of forecasts from $87 to $126 per share.
2026-07-28 03:41:13
Arrowhead Pharmaceuticals has completed enrollment in its global Phase 3 YOSEMITE clinical trial for zodasiran, an investigational RNAi therapeutic targeting homozygous familial hypercholesterolemia (HoFH). The study, which enrolled 70 patients, is expected to be completed in mid-2027, after which Arrowhead plans to seek regulatory approval. Zodasiran works by reducing ANGPTL3 expression to lower atherogenic lipoproteins, offering a new treatment approach for this rare genetic condition that causes severely elevated LDL-C and early-onset cardiovascular disease.
2026-07-27 12:40:30
Arrowhead Pharmaceuticals announced the completion of enrollment for its Phase 3 YOSEMITE clinical trial for zodasiran, an investigational RNA interference treatment for homozygous familial hypercholesterolemia (HoFH). While this is a significant milestone, the company's financial metrics reflect challenges in profitability and growth, with a GF Score of 49 and recent insider selling activity. Investors are advised to consider both the clinical progress and financial performance when evaluating ARWR stock.
